Kiniksa Pharmaceuticals International, plc KNSA Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's accounts receivable?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported accounts receivable of $23.22M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's accounts receivable changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's accounts receivable decreased by 42.0% year-over-year, from $40.07M to $23.22M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's accounts receivable?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's accounts receivable has grown at a 40.6% compound annual growth rate (CAGR), from $3.99M to $15.59M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.